Shoreline Biosciences Wins a Comprehensive Summary Judgement Victory on All Claims Brought by Fate Therapeutics and Whitehead Institute on iPSC Generation and Use
Shoreline Biosciences to Participate at the 2023 Wedbush Pacgrow Healthcare Conference
Shoreline Biosciences Appoints Kimberly Manhard to Board of Directors
San Diego, Calif., May 19, 2021 – Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK)
Shoreline Biosciences Appoints Vanessa L. Jacoby as Chief Financial Officer
Shoreline Biosciences, Inc. (Shoreline), a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced
Shoreline Biosciences Appoints Co-Founder William Sandborn, M.D. as Chief Medical Officer
Shoreline Biosciences, Inc. (Shoreline),a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targetedcellular immunotherapies derived from induced pluripotent stem cells (iPSC) for cancer and
Shoreline Biosciences Announces $43m Financing to Advance Pipeline of Allogeneic Natural Killer and Macrophage Cellular Immunotherapies Derived from Pluripotent Stem Cells
Shoreline Biosciences, Inc. (Shoreline),a biotechnology company developing intelligently designed allogeneic off-the-shelf, standardized and targeted natural killer (NK) and Macrophage cellular immunotherapies derived from induced pluripotent